Uterine Artery Embolization Improves Quality of Life in Patients with Pure Adenomyosis: A Single‑Center Experience

 

PDF Download Permissions and Reprints

Aim: The aim of the study was to assess clinical outcomes following uterine artery embolization (UAE) in the treatment of dysmenorrhea and menorrhagia related to pure adenomyosis. Materials and Methods: This was a retrospective analysis of 14 patients with dysmenorrhea and menorrhagia related to pure adenomyosis treated with UAE using polyvinyl alcohol (PVA) between January 2017 and September 2019. The baseline and 3-month and 12-month postintervention outcomes were assessed using Uterine Fibroid Symptom-Health-Related Quality of Life Questionnaire (UFS-QOL), Symptom Severity Score (SSS), and magnetic resonance imaging findings. The median age of the patients was 47 years (28–55). The main clinical presentation was dysmenorrhea and menorrhagia, with a median duration of symptom of 24 (12–84) months. All patients received combined estrogen-progestin and nonsteroidal anti-inflammatory drugs prior to UAE without clinical improvement. Results: According to UFS-QOL and SSS results, the score for distress level was statistically significantly reduced from baseline 4.6 (3.6–5) to 2.25 (1–3.37) (P = 0. 018) after 3 months, and remained stable 12 months later. The score of symptom level was statistically significantly reduced from 4 (3.6–5) at baseline to 1.6 (1–3.58) (P = 0. 018) after 3 months with maintained clinical satisfaction after 12-month follow-up. The junctional zone was statistically significantly reduced from baseline with a median of 33.5 mm (19–79 mm) to 25 mm (8–77 mm) after 3 and 12 months (P = 0.046). The incidence of post-UAE permanent amenorrhea is 71% with a mean age of 49 years. No patient underwent hysterectomy during the follow-up period. Conclusion: UAE using PVA can improve the quality of life in patients with menorrhagia and dysmenorrhea related to adenomyosis. However, larger prospective studies are needed to establish the long-term outcomes and risk of amenorrhea.

Publication History

Received: 12 November 2019
Received: 03 April 2020

Accepted: 10 April 2020

Article published online:
26 March 2021

© 2020. The Arab Journal of Interventional Radiology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. https://creativecommons.org/licenses/by-nc-nd/4.0/.

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

• References

• 1 Bird CC, McElin TW, Manalo-Estrella P. The elusive adenomyosis of the uterus—revisited. Am J Obstet Gynecol 1972;112:583-93.
• 2 Li JJ, Chung JP, Wang S, Li TC, Duan H. The Investigation and management of adenomyosis in women who wish to improve or preserve fertility. Biomed Res Int 2018;2018:6832685.
• 3 Azziz R. Adenomyosis: Current perspectives. Obstet Gynecol Clin North Am 1989;16:221-35.
• 4 Ravina JH, Herbreteau D, Ciraru-Vigneron N, Bouret JM, Houdart E, Aymard A,et al. Arterial embolisation to treat uterine myomata. Lancet 1995;346:671-2.
• 5 de Bruijn AM, Ankum WM, Reekers JA, Birnie E, van der Kooij SM, Volkers NA,et al. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial. Am J Obstet Gynecol 2016;215:745.e1-e12.
• 6 Goodwin SC, Spies JB, Worthington-Kirsch R, Peterson E, Pron G, Li S,et al. Uterine artery embolization for treatment of leiomyomata: Long-term outcomes from the FIBROID Registry. Obstet Gynecol 2008;111:22-33.
• 7 Popovic M, Puchner S, Berzaczy D, Lammer J, Bucek RA. Uterine artery embolization for the treatment of adenomyosis: A review. J Vasc Interv Radiol 2011;22:901-9.
• 8 de Bruijn AM, Smink M, Lohle PN, Huirne JA, Twisk JW, Wong C,et al. Uterine artery embolization for the treatment of adenomyosis: A systematic review and meta-analysis. J Vasc Interv Radiol 2017;28:1629-42.e1.
• 9 Coyne KS, Margolis MK, Bradley LD, Guido R, Maxwell GL, Spies JB. Further validation of the uterine fibroid symptom and quality-of-life questionnaire. Value Health 2012;15:135-42.
• 10 Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 2002;99:290-300.
• 11 Harding G, Coyne KS, Thompson CL, Spies JB. The responsiveness of the Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL). Health Qual Life Outcomes 2008;6:99.
• 12 Kim MD, Kim S, Kim NK, Lee MH, Ahn EH, Kim HJ,et al. Long-term results of uterine artery embolization for symptomatic adenomyosis. AJR Am J Roentgenol 2007;188:176-81.